PE20060881A1 - Sulfonamido-macrociclos y sus sales como inhibidores de tie2 y composiciones farmaceuticas que comprenden estos compuestos - Google Patents

Sulfonamido-macrociclos y sus sales como inhibidores de tie2 y composiciones farmaceuticas que comprenden estos compuestos

Info

Publication number
PE20060881A1
PE20060881A1 PE2006000007A PE2006000007A PE20060881A1 PE 20060881 A1 PE20060881 A1 PE 20060881A1 PE 2006000007 A PE2006000007 A PE 2006000007A PE 2006000007 A PE2006000007 A PE 2006000007A PE 20060881 A1 PE20060881 A1 PE 20060881A1
Authority
PE
Peru
Prior art keywords
alkyl
compounds
triaza
thia
dioxo
Prior art date
Application number
PE2006000007A
Other languages
English (en)
Inventor
Manfred Husemann
Wolfgang Schwede
Karl-Heinz Thierauch
Martina Schafer
Ulrich Lucking
Andreas Huth
Hans Briem
Georg Kettschau
Willian Karl Moberg
Rapado Liliana Parra
Frank Stelzer
Andrea Vescosi
Robert Reinhard
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20060881A1 publication Critical patent/PE20060881A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES H, ALQUILO C1-C10; R2 ES H, HALOGENO, CIANO, -NR4COR5, -S(O)2R4, ENTRE OTROS; R3 ES ALQUILO C1-C6, ALQUENILO C2-C6, CICLOALQUILO C3-C8, ARILO C6-C11, ENTRE OTROS; R4 Y R5 SON CADA UNO H, ALQUILO C1-C10, ALCOXI C1-C6, ALQUINILO C2-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-[4,4-DIOXO-4LAMBDA6-TIA-2,5,9-TRIAZA-1(2,4)-PIRIMIDIN-3(1,3)-BENCENOCICLONONAFAN-15-IL]-N,N-DIMETILBENCEN-SULFONAMIDA; 4-[4,4-DIOXO-4LAMBDA 6-TIA-2,5,9-TRIAZA-1(2,4)-PIRIMIDIN-3(1,3)-BENCENOCICLONONAFAN-15-IL]-BENCENAMINA, 4-[4,4-DIOXO-4LAMBDA6-TIA-2,5,9-TRIAZA-1(2,4)-PIRIMIDIN-3(1,3)-BENCENOCICLONONAFAN-15-IL]-N,N-DIMETILBENCEN-AMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA TIROSIN QUINASA RECEPTORA ENDOTELIAL Tie2 SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON EL CRECIMIENTO VASCULAR DESREGULADO TALES COMO TUMORES SOLIDOS, RETINOPATIA, ARTRITIS REUMATOIDE, PSORIASIS
PE2006000007A 2004-12-22 2006-01-03 Sulfonamido-macrociclos y sus sales como inhibidores de tie2 y composiciones farmaceuticas que comprenden estos compuestos PE20060881A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04090509A EP1674470A1 (en) 2004-12-22 2004-12-22 Sulfonamido-macrocycles as Tie2 inhibitors

Publications (1)

Publication Number Publication Date
PE20060881A1 true PE20060881A1 (es) 2006-10-01

Family

ID=34928853

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000007A PE20060881A1 (es) 2004-12-22 2006-01-03 Sulfonamido-macrociclos y sus sales como inhibidores de tie2 y composiciones farmaceuticas que comprenden estos compuestos

Country Status (15)

Country Link
EP (2) EP1674470A1 (es)
JP (1) JP2008524303A (es)
KR (1) KR20070099619A (es)
CN (1) CN101087798A (es)
AR (1) AR052175A1 (es)
AU (1) AU2005318361A1 (es)
BR (1) BRPI0519268A2 (es)
CA (1) CA2590742A1 (es)
GT (1) GT200500383A (es)
IL (1) IL182834A0 (es)
NO (1) NO20073818L (es)
PA (1) PA8658001A1 (es)
PE (1) PE20060881A1 (es)
TW (1) TW200635935A (es)
WO (1) WO2006066957A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1870416A1 (en) * 2006-06-21 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Sulphonamido-macrocycles as tie2 inhibitors
EP1873159A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
JP2011518836A (ja) 2008-04-24 2011-06-30 インサイト・コーポレイション 大環状化合物およびそれらのキナーゼ阻害剤としての使用
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP3356373B1 (en) 2015-09-29 2020-02-19 Bayer Pharma Aktiengesellschaft Novel macrocyclic sulfondiimine compounds
EP3359544B1 (en) 2015-10-08 2020-08-12 Bayer Pharma Aktiengesellschaft Novel modified macrocyclic compounds
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US11242356B2 (en) 2017-03-28 2022-02-08 Bayer Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
PL3601253T3 (pl) 2017-03-28 2022-01-17 Bayer Aktiengesellschaft Nowe hamujące ptefb związki makrocykliczne
CN115677616A (zh) * 2021-11-03 2023-02-03 中国药科大学 大环磺酰胺类化合物及其制备方法和医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524668A (ja) * 2002-03-01 2005-08-18 スミスクライン ビーチャム コーポレーション ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
GT200500383A (es) 2006-08-03
AR052175A1 (es) 2007-03-07
CA2590742A1 (en) 2006-06-29
CN101087798A (zh) 2007-12-12
WO2006066957A3 (en) 2006-08-31
WO2006066957A2 (en) 2006-06-29
BRPI0519268A2 (pt) 2009-01-06
TW200635935A (en) 2006-10-16
EP1674470A1 (en) 2006-06-28
KR20070099619A (ko) 2007-10-09
EP1844056A2 (en) 2007-10-17
IL182834A0 (en) 2007-08-19
PA8658001A1 (es) 2006-09-22
JP2008524303A (ja) 2008-07-10
AU2005318361A1 (en) 2006-06-29
NO20073818L (no) 2007-09-21

Similar Documents

Publication Publication Date Title
PE20060881A1 (es) Sulfonamido-macrociclos y sus sales como inhibidores de tie2 y composiciones farmaceuticas que comprenden estos compuestos
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
PE20061096A1 (es) Derivados de oxiindol como agonistas 5-ht4
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20051171A1 (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
PE20080659A1 (es) Benzotriazoles como moduladores de quinasas
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20060336A1 (es) Compuestos derivados de 1-amino-ftalazina como moduladores de mch1
PE20080068A1 (es) Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
PE20090775A1 (es) Nuevos derivados de biarilo
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20081164A1 (es) Nuevos compuestos 521
AR071609A1 (es) Inhibidores ciclicos de 11(beta) -hidroxiesteroide deshidrogenasa 1
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20060657A1 (es) Derivados de pirimidina como moduladores de ppar-alfa
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2

Legal Events

Date Code Title Description
FC Refusal